Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABCD-TO-SEIZE: Tofogliflozin vs oral semaglutide vs imeglimin in drug-naive type 2 diabetes
jRCTs051220187Recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised trial in type 2 diabetes mellitus (T2DM) comparing Tofogliflozin arm, Oral semaglutide arm and Imeglimin arm (3 arms). Started May 2023; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051220187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220187.